Page 23 - Company Codes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Dec 24, 2020 HYDERABAD, India, Dec. 24, 2020 /PRNewswire/ -- COVAXX's UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution Agreement leverages Aurobindo's existing development, commercial and manufacturing infrastructure Phase 2/3 clinical trials by COVAXX to begin early 1Q 2021 in Asia, Latin America and USA Important step in ensuring equitable access and global supply during worldwide pandemic Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Re...

A transcript of the presentation will be archived for 30 days following the event. About Oral Mucositis Mucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. per year and occurs in 40% of patients receiving chemotherapy. Mucositis can be severely de...

Vector Institute. It leverages past work of partners to address needs of infectious disease research with guidance from domain experts. "We are very proud to contribute to such an important effort in Canada, as it will have an impact not only on Canadian's healthcare but on COVID-19 patients around the world, as we learn more about the disease and ways we can treat patients with it," said George N. Nikopoulos, President and CEO of Mannin Research Inc. For more information, visit About Mannin Research Inc. Mannin Research is a research-stage biotechnology company focused on the discovery, de...

Published: Dec 21, 2020   BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform is pleased to announce the presentation of additional interim data results for the Company's lead therapeutic candidate, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, presented additional clinical data results with the treatm...

Published: Dec 17, 2020   BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform, announced today that Cytovance, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), have reached an agreement for license rights to use certain bacterial and mammalian cell lines and for GMP manufacturing services performed to date regar...